Literature DB >> 35929896

Definition and treatment approach of non-criteria clinical manifestations of antiphospholipid syndrome.

Ayten Yazıcı1.   

Abstract

Antiphospholipid syndrome (APS) is characterized by thrombosis and/or pregnancy morbidity with persistently positive antiphospholipid antibodies. However, in APS, there are several non-thrombotic clinical manifestations such as thrombocytopenia, cardiac valve disease, microthrombotic nephropathy, skin ulcer, or cognitive dysfunction. These non-criteria manifestations are relatively common and usually are non-responsive to anticoagulation. Among the non-criteria manifestations, thrombocytopenia, skin ulcers, migraine, and heart valve lesions are the most frequent manifestations described in APS. Limited data are available on the treatment of non-criteria manifestations of APS, and most therapeutic options are based on case reports or retrospective non-randomized studies. Although there is no consensus on the treatment of non-criteria manifestations of APS, anticoagulant therapy and immunomodulatory drugs could be combined in most patients.

Entities:  

Year:  2020        PMID: 35929896      PMCID: PMC7574762          DOI: 10.5152/eurjrheum.2020.20099

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  29 in total

Review 1.  Cognitive disorders and antiphospholipid antibodies.

Authors:  Cécile M Yelnik; Elizabeth Kozora; Simone Appenzeller
Journal:  Autoimmun Rev       Date:  2016-09-15       Impact factor: 9.754

Review 2.  The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features.

Authors:  Mirhelen M Abreu; Adriana Danowski; Denis G Wahl; Mary-Carmen Amigo; Maria Tektonidou; Marcelo S Pacheco; Norma Fleming; Vinicius Domingues; Savino Sciascia; Julia O Lyra; Michelle Petri; Munther Khamashta; Roger A Levy
Journal:  Autoimmun Rev       Date:  2015-01-29       Impact factor: 9.754

3.  A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome.

Authors:  Doruk Erkan; JoAnn Vega; Glendalee Ramón; Elizabeth Kozora; Michael D Lockshin
Journal:  Arthritis Rheum       Date:  2013-02

Review 4.  A cutaneous manifestation of antiphospholipid antibody syndrome.

Authors:  Lisa M DiFrancesco; Peter Burkart; James G Hoehn
Journal:  Ann Plast Surg       Date:  2003-11       Impact factor: 1.539

Review 5.  Diagnosis and classification of the antiphospholipid syndrome.

Authors:  Jose A Gómez-Puerta; Ricard Cervera
Journal:  J Autoimmun       Date:  2014-01-24       Impact factor: 7.094

Review 6.  Antiphospholipid antibodies and renal involvement.

Authors:  Antonietta Gigante; Maria Ludovica Gasperini; Rosario Cianci; Biagio Barbano; Konstantinos Giannakakis; Domenico Di Donato; Giorgio Fuiano; Antonio Amoroso
Journal:  Am J Nephrol       Date:  2009-08-28       Impact factor: 3.754

Review 7.  Neurologic manifestations of antiphospholipid syndrome.

Authors:  I F Ricarte; L A Dutra; F F Abrantes; F F Toso; O G P Barsottini; G S Silva; A W S de Souza; D Andrade
Journal:  Lupus       Date:  2018-05-17       Impact factor: 2.911

8.  The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe.

Authors:  R Cervera; M-C Boffa; M A Khamashta; G R V Hughes
Journal:  Lupus       Date:  2009-09       Impact factor: 2.911

Review 9.  Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.

Authors:  Savino Sciascia; Mary-Carmen Amigo; Dario Roccatello; Munther Khamashta
Journal:  Nat Rev Rheumatol       Date:  2017-08-03       Impact factor: 20.543

10.  Identification and treatment of APS renal involvement.

Authors:  M G Tektonidou
Journal:  Lupus       Date:  2014-10       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.